Home | AI powered stock trade ideas | Market Signals | Breaking Out | New Green Signal Stocks | Recent Red Arrow Top Signals | Recent Green Arrow Bottom Signals | Near Term Bottom Signals | Green Stocks with Most Upside to Analyst Target Price | New Long Term Green AI Signals | Big Tech Stocks | ETF Sector SPDRs | Solar Stocks | Chip Stocks | Airline Stocks | Social Media Stocks | Oil Stocks| Discount Store Stocks | Entertainment Stocks | EV Stocks | Restaurant Stocks | Heavy Equipment Stocks | Aerospace Stocks | Home Builders | Bank Stock Signals | Cruise Ship Stock Signals | Mining Stocks | Free AI Portfolio Analyzer | How to Read and Trade AI Powered Stock Charts| Stock Charts AI top 50 Stocks

Recently Featured Stock Charts
86% AI Stock Prediction Accuracy
Enter Stock Symbol to View AI powered Stock Chart


All Chart Prices Delayed at least 15 minutes

Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.

Last Price: 16.79 - Change: 0.3 - Change %: 1.8193
05/24/2024 16:10:00 EST

Elanco Animal Health (ELAN)

Industry: Drug Manufacturers - Specialty & Generic

Price Support Resistance

In the past 20 trading days, ELAN has been trading in a range between $17.20 and $13.15 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.

ELAN is trading below resistance at $17.20, about 2% to the upside. There is support at $15.89 -5% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.

Upside / Downside Potential

Elanco Animal Health $ELAN entered a Green zone 13 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $13.81, a potential down side of -16.25% from the recent price of 16.49. The stock is trading 5.7% (potential upside) below its 52 week high of $17.43 and 109.26 % (potential downside) above its 52 week low of $7.88 - based on the recent price.

Company Summary

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations.

ELAN Website


Elanco to Participate in Stifel 2024 Jaws and Paws Conference
GREENFIELD, Ind. , May 21, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Stifel 2024 Jaws and Paws Conference on Wednesday, May 29, 2024.
Source: PRNewsWire
Tue, 21 May 2024 08:00:00 -0400
Sentiment: Neutral
Elanco Animal Health (ELAN) CEO on Earnings
Elanco Animal Health (ELAN) CEO Jeffrey Simmons joins Oliver Renick to discuss ELAN's 1Q earnings. He talks about how ELAN's shares hit a 52-week high.
Source: Schwab Network
Wed, 08 May 2024 18:46:56 -0400
Sentiment: Positive
Elanco Animal Health (ELAN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Source: Zacks Investment Research
Wed, 08 May 2024 10:36:40 -0400
Sentiment: Positive
Elanco Makes A Bullish Move On Its First Quarter Beat; Are Pet Health Stocks Forging A Comeback?
Elanco stock surged Wednesday after the pet drugmaker beat first quarter expectations and hiked its profit guidance for the year.
Source: Investors Business Daily
Wed, 08 May 2024 10:20:38 -0400
Sentiment: Positive
Elanco Animal Health Reports First Quarter 2024 Results
First Quarter 2024 Financial Results Revenue of $1,205 million Reported Net income of $32 million, Adjusted Net income of $167 million Adjusted EBITDA of $294 million, or 24.4% of Revenue Reported EPS of $0.06, Adjusted EPS of $0.34 Net leverage ratio of 6.1x Adjusted EBITDA Year over year growth rates are meaningfully impacted by a shift in customer purchasing related to the ERP Blackout in 2023, with an estimated $90 to $110 million of revenue shift from the second quarter of 2023 into the first quarter of 2023 Updating full year 2024 financial guidance to reflect first quarter outperformance offset by expected unfavorable impact of foreign exchange rates: Revenue of $4,460 to $4,515 million, constant currency growth improves to 2% to 3% Reported Net Loss of $(3) to $(45) million; Reported EPS of $(0.01) to $(0.09) Adjusted EBITDA of $960 to $1,000 million; Adjusted EPS of $0.88 to $0.96 GREENFIELD, Ind. , May 8, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2024, provided guidance for the second quarter of 2024, and updated guidance for the full year 2024.
Source: PRNewsWire
Wed, 08 May 2024 06:28:00 -0400
Sentiment: Neutral
Instituions Institution %: 99.231
Last QTR Institution change: 18768306

Insiders %: 0.655
Insiders Purchases last QTR: 35000
Insiders Sales last QTR: 0
Insiders Net last QTR: 35000

Analyst Ratings
Target Price: 13.81
Overall Rating: 3.8667
Strong Buys (5): 5
Buys (4): 4
Holds (3): 5
Sells (2): 1
Strong Sells (1): 0

52 Week Hi: 17.43
52 Week Low: 7.88
Beta: 1.341
50 Day MA: 15.1948
200 Day MA: 13.455

Earnings / Revenue Trends
Qtr Earnings Growth YOY: -0.714
Qtr Revenue Growth YOY: -0.041
Forward PE: 15.1057
Trailing PE: 0

Benefits of StockChartsAI.com System:

  • Get a Daily List of Stocks Starting New Trends
  • Upload Your Stocks to Quickly See and Track Signals
  • Easy to Understand AI Stock Signals
  • Analysis of Historical Signal Trend Analysis for each stock
  • Search/View AI Stock Signals of Russel 1000 Stocks
  • Easy to Understand AI Stock Signals
  • And MUCH MUCH more!


Stock Analyzed Each Night


Easily Upload Track Your Stocks


See Lists of Stocks Starting New Trends

The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.